Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers
Open Access
- 8 April 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 28 (1), 1-13
- https://doi.org/10.1186/s12929-021-00719-5
Abstract
Thyroid hormone analogues—particularly, l-thyroxine (T4) has been shown to be relevant to the functions of a variety of cancers. Integrin αvβ3 is a plasma membrane structural protein linked to signal transduction pathways that are critical to cancer cell proliferation and metastasis. Thyroid hormones, T4 and to a less extend T3 bind cell surface integrin αvβ3, to stimulate the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway to stimulate cancer cell growth. Thyroid hormone analogues also engage in crosstalk with the epidermal growth factor receptor (EGFR)-Ras pathway. EGFR signal generation and, downstream, transduction of Ras/Raf pathway signals contribute importantly to tumor cell progression. Mutated Ras oncogenes contribute to chemoresistance in colorectal carcinoma (CRC); chemoresistance may depend in part on the activity of ERK1/2 pathway. In this review, we evaluate the contribution of thyroxine interacting with integrin αvβ3 and crosstalking with EGFR/Ras signaling pathway non-genomically in CRC proliferation. Tetraiodothyroacetic acid (tetrac), the deaminated analogue of T4, and its nano-derivative, NDAT, have anticancer functions, with effectiveness against CRC and other tumors. In Ras-mutant CRC cells, tetrac derivatives may overcome chemoresistance to other drugs via actions initiated at integrin αvβ3 and involving, downstream, the EGFR-Ras signaling pathways.Keywords
Funding Information
- E-Da Medical Center (EDAHP 109011)
This publication has 127 references indexed in Scilit:
- Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cellsCell Death & Disease, 2013
- Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal CancersGastroenterology, 2012
- The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityBMC Cancer, 2011
- Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironmentBiochemical Journal, 2011
- Extracellular signal-regulated kinase 1/2-mediated phosphorylation of p300 enhances myosin heavy chain I/ gene expression via acetylation of nuclear factor of activated T cells c1Nucleic Acids Research, 2011
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyBritish Journal of Cancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- Direct Binding of Integrin αvβ3 to FGF1 Plays a Role in FGF1 SignalingOnline Journal of Public Health Informatics, 2008
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005